Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ARK Innovation ETF (ARKK) vs BioNano Genomics Inc (BNGO) Price & Performance

ARK Innovation ETFTrade
BioNano Genomics IncTrade

Price performance (Past 24H)

Key statistics

ARK Innovation ETF vs BioNano Genomics Inc — how do they compare? ARK Innovation ETF trades at $81.26, while BioNano Genomics Inc trades at $1.2 (market cap $13.66M). The key difference: ARK Innovation ETF is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.

ARKKBNGO
52-Week High
$92.50$4.92
52-Week Low
$63.52$1.06
Market Cap
$13.66M
Sector
Health
Enterprise Value
$16.26M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ARK Innovation ETF

ARKK trades at $81.22, up 0.94% today, with a bullish technical signal from moving averages but a neutral stance from oscillators. The ETF's concentrated portfolio in disruptive innovation faces mixed sentiment, with recent news highlighting both buying activity in AI stocks like CoreWeave and concerns over high fees and underperformance versus the S&P 500. Key resistance is at $82, with support at $79.

Outlook remains volatile; ARKK offers exposure to high-growth themes like AI and space technology but carries significant concentration risk and fee drag. Investment opportunity hinges on successful bets in unprofitable ventures, while risks include dependency on Tesla and SpaceX performance and broader market shifts away from speculative growth.

BioNano Genomics Inc

BNGO trades at $1.19, up 2.59% today, with bullish technical signals from moving averages. The company shows improving financials with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable. Recent earnings have consistently beaten expectations, and analyst sentiment is positive with 57% buy ratings. Key developments include debt retirement and scientific publications highlighting optical genome mapping adoption.

The outlook is cautiously optimistic given improving fundamentals and positive analyst coverage, but significant risks remain due to persistent losses and negative cash flow. Investment opportunity lies in the company's technology adoption growth, while primary risks include profitability challenges and competitive pressures in the genomics space.

Returns comparison

Trailing returns across standard periods

About ARK Innovation ETF

The fund will invest under normal circumstances primarily (at least 65% of its assets) in domestic and foreign equity securities of companies that are relevant to the fund’s investment theme of disruptive innovation. Its investments in foreign equity securities will be in both developed and emerging markets. The fund may invest in foreign securities listed on foreign exchanges as well as American Depositary Receipts (ADRs) and Global Depositary Receipts (GDRs). The fund is non-diversified.

Read more on ARKK

About BioNano Genomics Inc

Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.

Read more on BNGO